Purpose: To evaluate long-term outcome after revitrectomy with autologous platelet concentrate (APC) or whole blood (WB) in persistent idiopathic macular hole (MH) after vitrectomy with internal limiting membrane (ILM) peeling. Procedures: Retrospective study of 75 eyes with persistent MH after vitrectomy with ILM peeling and gas. All patients underwent revitrectomy with gas and APC (n = 61) or WB (n = 14). Main outcome measures were anatomical closure rate and postoperative best-corrected visual acuity (BCVA). Results: Closure rate after revitrectomy was 85.2% (52/61) in the APC group and 7.1% (1/14) in the WB group. Median follow-up was 58 (range 3-147) months. Median BCVA (logMAR) in patients with finally closed MHs was 0.4 ± 0.3. Patients with defects of the ellipsoid zone had significantly worse postoperative BCVA. Morphological MH configuration (atrophic or elevated edges) did not correlate with final closure rate. Conclusions: Revitrectomy with APC and gas is a very effective treatment in persistent MH after vitrectomy with ILM peeling and gas.

Keywords:
Autologous platelet concentrate, Autologous whole blood, Persistent macular hole, Revitrectomy
1.
García-Layana A, García-Arumí J, Ruiz-Moreno JM, Arias-Barquet L, Cabrera-López F, Figueroa MS: A review of current management of vitreomacular traction and macular hole. J Ophthalmol 2015;2015:809640.
2.
Spiteri CK, Lois N, Scott NW, Burr J, Cook J, Boachie C, Tadayoni R, la Cour M, Christensen U, Kwok AK: Vitrectomy with internal limiting membrane peeling versus no peeling for idiopathic full-thickness macular hole. Ophthalmology 2014;121:649-655.
3.
Morescalchi F, Costagliola C, Gambicorti E, Duse S, Romano MR, Semeraro F: Controversies over the role of internal limiting membrane peeling during vitrectomy in macular hole surgery. Surv Ophthalmol 2016;62:58-69.
4.
Christensen UC, Kroyer K, Sander B, Larsen M, Henning V, Villumsen J, la Cour M: Value of internal limiting membrane peeling in surgery for idiopathic macular hole stage 2 and 3: a randomised clinical trial. Br J Ophthalmol 2009;93:1005-1015.
5.
Lois N, Burr J, Norrie J, Vale L, Cook J, McDonald A, Boachie C, Ternent L, McPherson G; Full-Thickness Macular Hole and Internal Limiting Membrane Peeling Study (FILMS) Group: Internal limiting membrane peeling versus no peeling for idiopathic full thickness macular hole: a pragmatic randomised controlled trial. Invest Ophthalmol Vis Sci 2011;52:1586-1592.
6.
D'Souza MJ, Chaudhary V, Devenyi R, Kertes PJ, Lam WC: Re-operation of idiopathic full-thickness macular holes after initial surgery with internal limiting membrane peel. Br J Ophthalmol 2011;95:1564-1567.
7.
Moisseiev E, Fabian ID, Moisseiev J, Barak A: Outcomes of repeated pars plana vitrectomy for persistent macular holes. Retina 2013;33:1137-1143.
8.
Cillino S, Cillino G, Ferraro LL, Casuccio A: Treatment of persistently open macular holes with heavy silicone oil (Densiron 68) versus C3F6. A prospective randomized study. Retina 2016;36:688-694.
9.
Rizzo S, Genovesi-Ebert F, Vento A, Cresti F, Miniaci S, Romagnoli MC: Heavy silicone oil (Densiron-68) for the treatment of persistent macular holes: Densiron-68 endotamponade for persistent macular holes. Graefes Arch Clin Exp Ophthalmol 2009;247:1471-1476.
10.
Lappas A, Foerster AM, Kirchhof B: Use of heavy silicone oil (Densiron-68) in the treatment of persistent macular holes. Acta Ophthalmol 2009;87:866-870.
11.
Hillenkamp J, Kraus J, Framme C, Jackson TL, Roider J, Gabel VP, Sachs HG: Retreatment of full-thickness macular hole: predictive value of optical coherence tomography. Br J Ophthalmol 2007;91:1445-1449.
12.
Valldeperas X, Wong D: Is it worth reoperating on macular holes? Ophthalmology 2008;115:158-163.
13.
Dimopoulos S, William A, Voykov B, Ziemssen F, Bartz-Schmidt KU, Spitzer MS: Anatomical and visual outcomes of autologous thrombocyte serum concentrate in the treatment of persistent full-thickness idiopathic macular hole after ILM peeling with brilliant blue G and membrane blue dual. Acta Ophthalmol 2017;95:e429-e430.
14.
Ezra E, Aylward WG, Gregor ZJ: Membranectomy and autologous serum for the retreatment of full-thickness macular holes. Arch Ophthalmol 1997;115:1276-1280.
15.
Pires J, Nadal J, Gomes NL: Internal limiting membrane translocation for refractory macular holes. Br J Ophthalmol 2017;101:377-382.
16.
Chen SN, Yang CM: Lens capsular flap transplantation in the management of refractory macular hole from multiple etiologies. Retina 2016;36:163-170.
17.
Szigiato AA, Gilani F, Walsh MK, Mandelcorn ED, Muni RH: Induction of macular detachment for the treatment of persistent or recurrent idiopathic macuar holes. Retina 2016;36:1694-1698.
18.
Paques M, Chastang C, Mathis A, Sahel J, Massin P, Dosquet C, Korobelnik JF, Le Gargasson JF, Gaudric A: Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, double-masked, randomized trial. Platelets in Macular Hole Surgery Group. Ophthalmology 1999;106:932-938.
19.
Hoerauf H, Kluter H, Joachimmeyer E, Roider J, Framme C, Schlenke P, Kirchner H, Lagua H: Results of vitrectomy and the no-touch-technique using autologous adjuvants in macular hole treatment. Int Ophthalmol 2001;24:151-159.
20.
Kapoor KG, Khan AN, Tieu BC, Khurshid GS: Revisiting autologous platelets as an adjuvant in macular hole repair: chronic macular holes without prone positioning. Ophthalmic Surg Lasers Imaging 2012;43:291-295.
21.
Gaudric A, Massin P, Paques M, Santiago PY, Guez JE, Le Gargasson JF, Mundler O, Drouet L: Autologous platelet concentrate for the treatment of full thickness macular holes. Graefes Arch Clin Exp Ophthalmol 1995;233:549-554.
22.
Lacci MK, Dardik A: Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med 2010;83:1-9.
23.
Carter MJ, Fylling CP, Parnell LK: Use of platelet rich plasma gel on wound healing: a systematic review and meta-analysis. Eplasty 2011;11:e38.
24.
Andia I, Abate M: Platelet-rich plasma: underlying biology and clinical correlates. Regen Med 2013;8:645-658.
25.
Su CY, Kuo YP, Nieh HL, Tseng YH, Burnouf T: Quantitative assessment of the kinetics of growth factors released from platelet gel. Transfusion 2008;48:2414-2420.
26.
Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E: Platelets and wound healing. Front Biosci 2008;13:3532-3548.
27.
Obolenskiy VN, Ermolova DA, Laberko LA, Semenova TV: Efficacy of platelet rich plasma for the treatment of chronic wounds. EWMA J 2014;14:37-41.
28.
Martin P: Wound healing - aiming for perfect skin regeneration. Science 1997;276:75-81.
29.
Kakudo N, Kushida S, Ogura N, Hara T, Suzuki K, Kusomoto K: The use of autologous platelet rich plasma in the treatment of intractable skin ulcer. Open J Reg Med 2012;1:29-32.
30.
Hara S, Sakuraba T, Nakazawa M: Morphological changes of retinal pigment epithelial and glial cells at the site of experimental retinal holes. Graefes Arch Clin Exp Ophthalmol 2000;238:690-695.
31.
Burmeister SL, Hartwig D, Limb GA, Kremling C, Hoerauf H, Müller M, Geerling G: Effect of various platelet preparations on retinal muller cells. Invest Ophthalmol Vis Sci 2009;50:4881-4886.
32.
Velhagen KH, Druegg A, Rieck P: Proliferation and wound healing of retinal pigment epithelium cells in vitro. Effect of human thrombocyte concentrate, serum and PDGF. Ophthalmologe 1999;96:77-81.
33.
Campochiaro PA, Hackett SF, Vinores SA, Freund J, Csaky C, LaRochelle W, Henderer J, Johnson M, Rodriguez IR, Friedman Z: Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells. J Cell Sci 1994;107:2459-2469.
34.
Kamei M, Kawasaki A, Tano Y: Analysis of extracellular matrix synthesis during wound healing of retinal pigment epithelial cells. Microsc Res Tech 1998;42:311-316.
35.
Purtskhvanidze K, Treumer F, Junge O, Hedderich J, Roider J, Hillenkamp J: The long-term course of functional and anatomical recovery after macular hole surgery. Invest Ophthalmol Vis Sci 2013;54:4882-4891.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.